摘要
应用无创性生物标志物和肝脏瞬时弹性成像技术,可以更加精准地评估慢性乙型肝炎(chronic hepatitis B,CHB)患者的疾病严重度,有助于确定抗病毒治疗的时机,通过核苷(酸)类似物[nucleos(t)ide analogues,NA]长期抗病毒治疗,可以使患者临床获益,选择合适的患者,通过优化治疗方案,诸如应用NA和聚乙二醇干扰素联合或序贯治疗,可以提高HBeAg血清学转换率和HBsAg清除率,应用患者年龄、性别、肝硬化状态、病毒学因素、治疗应答情况和肝脏瞬时弹性成像检测,可以预测CHB患者发生肝细胞癌(hepatocellularcarcinoma,HCC)的风险,然而,如何进一步降低HCC的发生风险,仍然是CHB临床管理的重大挑战.
This paper reviews the recent advances in the assessment and treatment of chronic hepatitis B with regard to predicting inflammation and fibrosis with non-invasive biomarkers and transient elastography,clinical benefits of long-term nucleos(t)ide analog(NA)antiviral therapy,serological benefits(HBeAg and HBsAg loss)of concurrent or sequential NAs and pegylated interferon,as well as risk factors for the development of hepatocellular carcinoma.
作者
张莉
张福奎
Li Zhang;Fu-Kui Zhang(Department of Gastroenterology,Beijing Shijingshan Hospital,Beijing 100043,China)
出处
《世界华人消化杂志》
CAS
2019年第4期209-219,共11页
World Chinese Journal of Digestology
